Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib plus apatinib in platinum-sensitive advanced ovarian cancer after prior PARP inhibitor progression
ChiCTR2300074862Phase 4Recruiting
- Sponsor
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Start
- Aug 2023
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fluzoparib and Rivoceranib in ovarian cancer, sponsored by Shandong Provincial Hospital Affiliated to Shandong First Medical University. Primary endpoint: Adverse reactions. Started Aug 2023; status: recruiting.
02
Drugs
fluzoparibRivoceranib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on ChiCTR2300074862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074862.